nitazoxanide - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.46 [0.03, 8.02]< 10%1 study (1/-)70.0 %highnot evaluable lowcrucial-
deaths 1.02 [0.02, 51.70]< 10%1 study (1/-)49.6 %highnot evaluable lowcrucial-
clinical deterioration 1.02 [0.29, 3.58]< 10%1 study (1/-)48.7 %highnot evaluable lowimportant-
clinical improvement 0.81 [0.52, 1.27]> 10%1 study (1/-)18.1 %highnot evaluable lowimportant-
clinical improvement (7-day) 0.81 [0.52, 1.27]> 10%1 study (1/-)18.1 %highnot evaluable lowimportant-
ICU admission 4.11 [0.18, 91.83]< 10%1 study (1/-)18.9 %highnot evaluable lownon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.